Danielle Portnik MBiotech, CHE

Danielle Portnik is an established Canadian leader who has also taken on important work on the international stage. She joined Emergent in May 2023, where she leads the Canadian organizations to maximize impact across Canada and the communities it aims to serve. Before joining Emergent, Danielle diversified and broadened her perspective in diagnostics as the Regional Business Director, International with Ambry Genetics, where she led the international business development strategy for Ambry's precision medicine offering in the Americas, Europe, and ANZEA.

She has also held numerous roles across the pharmaceutical space in product management, marketing and sales oversight, medical affairs, and account management, and has led strategy and execution for drug and medical device portfolios. Her strong business-clinical background, passion, and drive have curated innovative, high-impact programs and healthcare partnerships. She has been recognized by both local and global colleagues for her leadership, unique strategies, and outstanding business growth, and by national and international organizations for her contributions to excellence in the field. In 2023, she was nominated for Acquisition International's 2023 Most Influential Businesswomen Award and WXN's Top 100 for her work.